Last reviewed · How we verify
Comparator: Rizatriptan
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.
At a glance
| Generic name | Comparator: Rizatriptan |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Rizatriptan binds to 5-HT1B and 5-HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. This causes vasoconstriction of dilated cranial arteries and reduces the release of vasoactive neuropeptides involved in migraine pathophysiology, thereby terminating acute migraine attacks.
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
- Dizziness
- Somnolence
- Asthenia/fatigue
- Chest pain/pressure
- Palpitations
- Nausea
Key clinical trials
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) (PHASE3)
- Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) (PHASE3)
- Treatment of Multiple Attacks of Acute Migraine (0462-025) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Rizatriptan CI brief — competitive landscape report
- Comparator: Rizatriptan updates RSS · CI watch RSS
- Organon and Co portfolio CI